Evidence map›Paper›PMID 39160183›Full record

ArticleScientific reports2024

Association of olfactory and cognitive function test scores with hippocampal and amygdalar grey matter volume: a cross-sectional study.

Shuichi Sato, Takao Imaeda, Shunji Mugikura, Naoko Mori, Masaki Takanashi, Kazumi Hayakawa, Tomo Saito, Makiko Taira, Akira Narita, Mana Kogure and 15 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. [Depressive disorders and olfactory dysfunction].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Shuichi SatoToyota Central Research and Development Laboratories, Inc., Nagakute, 480-1192, Japan. shuichi-sato@mosk.tytlabs.co.jp.
Takao ImaedaToyota Central Research and Development Laboratories, Inc., Nagakute, 480-1192, Japan.
Shunji MugikuraTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Naoko MoriTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Masaki TakanashiToyota Central Research and Development Laboratories, Inc., Nagakute, 480-1192, Japan.
Kazumi HayakawaToyota Central Research and Development Laboratories, Inc., Nagakute, 480-1192, Japan.
Tomo SaitoTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Makiko TairaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Akira NaritaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Mana KogureTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Ippei ChibaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Rieko HatanakaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Kumi NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Ikumi KannoTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Ryosuke IshiwataTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Tomohiro NakamuraTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Ikuko N MotoikeTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Naoki NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Seizo KoshibaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Kengo KinoshitaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Shinichi KuriyamaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Soichi OgishimaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Fuji NagamiTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Nobuo FuseTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Atsushi HozawaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan. hozawa@megabank.tohoku.ac.jp.

Funding

Japan Agency for Medical Research and Development JP21tm0124005
6 · The paper itself

Abstract

Few population-based studies including younger adults have examined the potential of olfactory function tests to capture the degree of atrophy in memory-associated brain regions, which cannot be adequately explained by cognitive function tests screening for cognitive impairment. This population-based study investigated associations between high-resolution olfactory test data with few odours and grey matter volumes (GMVs) of the left and right hippocampi, amygdala, parahippocampi, and olfactory cortex, while accounting for differences in cognitive decline, in 1444 participants (aged 31-91 years). Regression analyses included intracranial volume (ICV)-normalised GMVs of eight memory-related regions as objective variables and age, sex, education duration, smoking history, olfaction test score, and the Montreal Cognitive Assessment-Japanese version (MoCA-J) score as explanatory variables. Significant relationships were found between olfactory test scores and ICV-normalised GMVs of the left and right hippocampi and left amygdala (p = 0.020, 0.024, and 0.028, respectively), adjusting for the MoCA-J score. The olfactory test score was significantly related to the right amygdalar GMV (p = 0.020) in older adults (age ≥ 65 years). These associations remained significant after applying Benjamini-Hochberg multiple testing correction (false discovery rate < 0.1). Therefore, olfactory and cognitive function tests may efficiently capture the degree of atrophy in the hippocampi and amygdala, especially in older adults.

Indexed as

AmygdalaCognitionGray MatterHippocampusMagnetic Resonance ImagingAdultAgedAged, 80 and overAtrophyCognitive DysfunctionCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsBrain atrophyCognitive functionCross-sectional studiesGrey matter volumeMultiple regressionOlfactory function

Identifiers

PMID39160183
PMCPMC11333722

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.